Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026GlobeNewsWire • 10/23/26
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire • 10/22/26
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoGlobeNewsWire • 10/21/26
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026GlobeNewsWire • 10/07/26
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials TranscriptSeeking Alpha • 09/24/26
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia GravisGlobeNewsWire • 09/24/26
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial ResultsGlobeNewsWire • 08/11/26
Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program AdvancementSeeking Alpha • 07/29/26
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-celGlobeNewsWire • 07/27/26
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage TransitionGlobeNewsWire • 06/22/26
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?The Motley Fool • 06/08/26
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid ArthritisGlobeNewsWire • 06/03/26
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial ResultsGlobeNewsWire • 05/12/26
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial OfficerGlobeNewsWire • 05/04/26
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia GravisSeeking Alpha • 04/22/26
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual MeetingGlobeNewsWire • 04/21/26
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small SampleSeeking Alpha • 04/21/26
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 WeeksGlobeNewsWire • 04/20/26
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026GlobeNewsWire • 04/09/26